胰腺癌化疗的应用前景_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

陶蔚 , 赵玉沛

Corresponding author：

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 陶蔚,赵玉沛. 胰腺癌化疗的应用前景. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 1998, 5(6): 377-379. doi: Copy

1.	Ahlgren JD.Chemotherapy of pancratic carcinoma. Cancer, 1996; 78(3)∶654.
2.	O’connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol, 1985; 3(3)∶1032.
3.	Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg, 1994; 168(4)∶361.
4.	Gastrointestinal tumor study group. phase Ⅱ studies of drug combinations in advanced pancreatic carcinoma： fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol, 1986; 4(5)∶1794.
5.	Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin, JAMA, 1985; 253(10)∶2061.
6.	Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action and selfpotentiation. Semi Oncol, 1995; 22(4 Suppl 11)∶3.
7.	Moore M. A randomized trial of gemcitabine (GEM) versus 5Fu as first line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol, 1995; 14(1)∶199.
8.	Rothenberg ML. A phase Ⅱ trial of gemcitabine in patients with 5Furefractory pancreas cancer. Ann Oncol, 1996; 7(4)∶347.
9.	Rougier D, De Forni M, Adenis A, et al. Phase Ⅱ study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol, 1994; 13(1)∶200.
10.	Lavelle F, Bissery MC, Andre S, et al. Preclinical evaluation of CPTⅡ and it active metabolite SN38. Semin Oncol, 1996; 23(1 Duppl 3)∶11.
11.	Wagerner DJT, Verdonk HER, Dirix LY, et al. Phase Ⅱ trial of CPTⅡ in the patients with advanced pancreatic cancer, an EORTC early clinical trial group study. Ann Oncol, 1995; 6(1)∶129.
12.	Wils JA. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer, 1993; 29A(2)∶203.
13.	Nicolson M.Cisplatin and protracted venous infusion 5fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma.Ann Oncol,1995; 6(8)∶801.
14.	Cornelison TL, Goldberg JM, Piver MS. Taxol and paltinum chemotherapy in the treatment of pancreatic and jujunal carcinoma. J Surg Oncol, 1995; 59(3)∶204.
15.	Bold RJ. Alltransretinoic acid (ATRA) inhibits growth of human pancreatic cancer cell lines. Pancreas, 1996; 12(2)∶189.
16.	Taylor DD. Enhancement of antitumor effects of combined chemoimmunotherapy. J Immunother, 1993; 13(2)∶91.
17.	Clary BM. Active immunotherapy of pancreatic cancer with tumor cells genetically egineered to secret multiple cytokines. Surgery, 1996; 120(2)∶174.
18.	郑扶民，陈英忠.未能切除的胰腺癌行区域性导向化疗临床应用报告.中国实用外科杂志，1995； 15(4)∶213.

1. Ahlgren JD.Chemotherapy of pancratic carcinoma. Cancer, 1996; 78(3)∶654.
2. O’connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol, 1985; 3(3)∶1032.
3. Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg, 1994; 168(4)∶361.
4. Gastrointestinal tumor study group. phase Ⅱ studies of drug combinations in advanced pancreatic carcinoma： fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol, 1986; 4(5)∶1794.
5. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin, JAMA, 1985; 253(10)∶2061.
6. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action and selfpotentiation. Semi Oncol, 1995; 22(4 Suppl 11)∶3.
7. Moore M. A randomized trial of gemcitabine (GEM) versus 5Fu as first line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol, 1995; 14(1)∶199.
8. Rothenberg ML. A phase Ⅱ trial of gemcitabine in patients with 5Furefractory pancreas cancer. Ann Oncol, 1996; 7(4)∶347.
9. Rougier D, De Forni M, Adenis A, et al. Phase Ⅱ study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol, 1994; 13(1)∶200.
10. Lavelle F, Bissery MC, Andre S, et al. Preclinical evaluation of CPTⅡ and it active metabolite SN38. Semin Oncol, 1996; 23(1 Duppl 3)∶11.
11. Wagerner DJT, Verdonk HER, Dirix LY, et al. Phase Ⅱ trial of CPTⅡ in the patients with advanced pancreatic cancer, an EORTC early clinical trial group study. Ann Oncol, 1995; 6(1)∶129.
12. Wils JA. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer, 1993; 29A(2)∶203.
13. Nicolson M.Cisplatin and protracted venous infusion 5fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma.Ann Oncol,1995; 6(8)∶801.
14. Cornelison TL, Goldberg JM, Piver MS. Taxol and paltinum chemotherapy in the treatment of pancreatic and jujunal carcinoma. J Surg Oncol, 1995; 59(3)∶204.
15. Bold RJ. Alltransretinoic acid (ATRA) inhibits growth of human pancreatic cancer cell lines. Pancreas, 1996; 12(2)∶189.
16. Taylor DD. Enhancement of antitumor effects of combined chemoimmunotherapy. J Immunother, 1993; 13(2)∶91.
17. Clary BM. Active immunotherapy of pancreatic cancer with tumor cells genetically egineered to secret multiple cytokines. Surgery, 1996; 120(2)∶174.
18. 郑扶民，陈英忠.未能切除的胰腺癌行区域性导向化疗临床应用报告.中国实用外科杂志，1995； 15(4)∶213.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

胰腺癌化疗的应用前景

Abstract Full text Figures/Tables Video References Cited by

Format

Content